Table 1. Characteristics for 18... | American Society of Hematology

Table 1.

Characteristics for 18 HIV-1—infected patients

	CD4 cells/mm³	CD8 cells/mm³				DCs in PBMCs, %			No. DCs/mL blood
Patient no.	CD4 cells/mm³	CD8 cells/mm³			HIV VL copies/mL	HAART	ACTG stage	MDC	PDC	MDC	PDC
Patients with KS
1	576	1146	< 50	3TC, aba, lop, ten	T0I0	0.33	0.08	2438	600
2	484	1449	< 50	3TC, ind, D4T	T0I0	0.23	0.01	2901	139
3	392	756	< 50	rit, ind, AZT, 3TC	T0I0	0.21	0.01	1608	112
4	363	663	< 50	3TC, aba, nev	T0I0	0.31	0.04	1248	164
5	147	705	< 50	comb, nev	T1I1	0.28	0.03	1175	137
6	169	406	< 50	comb, efa	T0I1	0.24	0.05	1673	357
7	104	317	374 490	AZT, 3TC, efa	T1I0	0.15	0.01	980	67
8	115	1273	450 614	AZT, 3TC, efa	T1I0	0.17	0.02	717	100
9	128	251	5 311	Trizivir, efa	T1I0	0.3	0.02	602	42
10	132	617	< 50	lop, ten, DDI	T1I0	0.16	0.07	80	34
11	28	329	< 50	comb, efa	T1I0	0.16	0.02	161	20
12	52	188	< 50	Trizivir, efa	T1I0	—		—	—
Patients without KS
13	526	930	< 50	Trizivir	NA	0.22	0.19	1980	1760
14	364	369	< 50	comb, efa	NA	0.26	0.25	1813	1729
15	168	274	< 50	comb, rit, ind	NA	0.29	0.27	1698	1581
16	126	758	176 555	D4T, 3TC, aba	NA	0.28	0.19	1321	882
17	148	236	3 658	comb, efa	NA	0.29	0.25	488	417
18	64	197	< 50	DDI, 3TC, efa	NA	0.18	0.22	175	221

	CD4 cells/mm³	CD8 cells/mm³				DCs in PBMCs, %			No. DCs/mL blood
Patient no.	CD4 cells/mm³	CD8 cells/mm³			HIV VL copies/mL	HAART	ACTG stage	MDC	PDC	MDC	PDC
Patients with KS
1	576	1146	< 50	3TC, aba, lop, ten	T0I0	0.33	0.08	2438	600
2	484	1449	< 50	3TC, ind, D4T	T0I0	0.23	0.01	2901	139
3	392	756	< 50	rit, ind, AZT, 3TC	T0I0	0.21	0.01	1608	112
4	363	663	< 50	3TC, aba, nev	T0I0	0.31	0.04	1248	164
5	147	705	< 50	comb, nev	T1I1	0.28	0.03	1175	137
6	169	406	< 50	comb, efa	T0I1	0.24	0.05	1673	357
7	104	317	374 490	AZT, 3TC, efa	T1I0	0.15	0.01	980	67
8	115	1273	450 614	AZT, 3TC, efa	T1I0	0.17	0.02	717	100
9	128	251	5 311	Trizivir, efa	T1I0	0.3	0.02	602	42
10	132	617	< 50	lop, ten, DDI	T1I0	0.16	0.07	80	34
11	28	329	< 50	comb, efa	T1I0	0.16	0.02	161	20
12	52	188	< 50	Trizivir, efa	T1I0	—		—	—
Patients without KS
13	526	930	< 50	Trizivir	NA	0.22	0.19	1980	1760
14	364	369	< 50	comb, efa	NA	0.26	0.25	1813	1729
15	168	274	< 50	comb, rit, ind	NA	0.29	0.27	1698	1581
16	126	758	176 555	D4T, 3TC, aba	NA	0.28	0.19	1321	882
17	148	236	3 658	comb, efa	NA	0.29	0.25	488	417
18	64	197	< 50	DDI, 3TC, efa	NA	0.18	0.22	175	221

Twelve patients had histologically confirmed active KS; 6 HIV-1—infected patients were matched to these for CD4 count (within 50 cells/mm³) and HIV-1 RNA viral load (within 0.5 Log₁₀) such that patients 1 and 2 (KS negative) were matched to patient 13 (KS positive), patients 3 and 4 were matched to patient 14, and so on. All patients were male, aged 25 to 40 years. The 6 patients without KS were confirmed as KSHV negative by PCR to 2 sections of the unique KSHV gene K1. The percentage and numbers of myeloid (CD11c⁺) and plasmacytoid (CD11c^-) DCs are shown. Antiretrovirals include abacavir (aba), combivir (comb), efavirenz (efa), indinivir (ind), lopinivir (lop), nevirapine (nev), and ritonavir (rit). Median length of time on HAART was 3 years (range, 1-7 years). There were no statistically significant differences between the 2 groups for the median length of time on HAART, number of previous regimens, or CD8 counts (none of these criteria were included in the matching of KS-positive to -negative patients). DC subsets were not counted for 1 patient with KS. ACTG indicates AIDS Clinical Trials Group Oncology Committee,⁴² where (briefly) tumor status (0 indicates cutaneous only; 1, more than cutaneous disease) and immunologic status (0 indicates a CD4 count < 150; 1, CD4 count > 150 cells/mm³) are used to stage KS; NA indicates not applicable.

View Large

This Feature Is Available To Subscribers Only